25 research outputs found
Trends in the curative treatment of localized prostate cancer after the introduction of prostate-specific antigen: Data from the Rotterdam Cancer Registry
High postoperative risk after pneumonectomy in elderly patients with right-sided lung cancer
The present study investigated postoperative mortality (POM), its
predictors and relationship with long-term survival in patients who
underwent surgery for lung cancer. The 30-day mortality after thoracotomy
in 1,830 patients from the Flemish multicentre hospital-based lung cancer
registry was analysed according to patient, tumour, treatment and hospital
characteristics and compared with 5-yr survival figures for the same
patients. Overall POM was 4.4%. In univariate analysis age, extent of
surgery and low hospital volume were associated with a higher POM. In
multiple regression analysis age, extent of surgery and side of the
pneumonectomy proved to be independent predictors of POM. In patients aged
>70 yrs who underwent right-sided pneumonectomy POM was 17.8%. Overall,
mortality was comparable to published series from referral centres. Age
and extent of resection are the main predictors of postoperative mortality
in lung-cancer patients. In the operable elderly patient, age alone does
not justify denying the survival benefit experienced by resection of lung
cancer. The high mortality after right-sided pneumonectomy in elderly
patients warrants caution, as the treatment benefit may become marginal
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer
BACKGROUND: Screening for prostate cancer advances the time of diagnosis
(lead time) and detects cancers that would not have been diagnosed in the
absence of screening (overdetection). Both consequences have considerable
impact on the net benefits of screening. METHODS: We developed simulation
models based on results of the Rotterdam section of the European
Randomized Study of Screening for Prostate Cancer (ERSPC), which enrolled
42,376 men and in which 1498 cases of prostate cancer were identified, and
on baseline prostate cancer incidence and stage distribution data. The
models were used to predict mean lead times, overdetection rates, and
ranges (corresponding to approximate 95% confidence intervals) associated
with different screening programs. RESULTS: Mean lead times and rates of
overdetection depended on a man's age at screening. For a single screening
test at age 55, the estimated mean lead time was 12.3 years (range =
11.6-14.1 years) and the overdetection rate was 27% (range = 24%-37%); at
age 75, the estimates were 6.0 years (range = 5.8-6.3 years) and 56%
(range = 53%-61%), respectively. For a screening program with a 4-year
screening interval from age 55 to 67, the estimated mean lead time was
11.2 years (range = 10.8-12.1 years), and the overdetection rate was 48%
(range = 44%-55%). This screening program raised the lifetime risk of a
prostate cancer diagnosis from 6.4% to 10.6%, a relative increase of 65%
(range = 56%-87%). In annual screening from age 55 to 67, the estimated
overdetection rate was 50% (range = 46%-57%) and the lifetime prostate
cancer risk was increased by 80% (range = 69%-116%). Extending annual or
quadrennial screening to the age of 75 would result in at least two cases
of overdetection for every clinically relevant cancer detected.
CONCLUSIONS: These model-based lead-time estimates support a prostate
cancer screening interval of more than 1 year
Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study
Background. Malignant peritoneal mesothelioma (MPM)
is a rare and aggressive disease. Recently, focus has shifted
toward a more aggressive and multimodal treatment
approach. This study aimed to assess the patterns of care
and survival for MPM patients in the Netherlands on a
nationwide basis.
Methods. The records of patients with a diagnosis of
MPM from 1993 to 2016 were retrieved from the Dutch
Cancer Registry. Data regarding diagnosis, staging, treatment, and survival were extracted. Cox regression analyses
and Kaplan–Meier survival curves were used to study
overall survival.
Results. Between 1993 and 2016, MPM was diagnosed for
566 patients. Overall, the prognosis was very poor (24%
1-year survival). The most common morphologic subtype
was the epithelioid subtype (88%), follo
Volwassen kankerpatienten overleven langer in Nederland. 5-jaarsoverleving 12% toegenomen tussen 1989-1993 en 2004-2008
Doel: Inzicht geven in de overleving van kankerpatiënten om verbeteringen in de kankerzorg te kunnen volgen. Opzet: Retrospectieve, bevolkingsbrede cohortstudie. Methode: Voor dit onderzoek werden gegevens van de Nederlandse Kankerregistratie gebruikt. Van alle gediagnosticeerde kankerpatiënten uit de periode 1989-2008 in Nederland werden gegevens over de vitale status verzameld in ziekenhuizen, bevolkingsregisters en de gemeentelijke basisadministratie persoonsgegevens. Per vorm van kanker werden voor de leeftijd gestandaardiseerde relatieve overlevingcijfers berekend. Resultaten: De 5-jaarsoverleving van alle patiënten samen steeg van 47% in 1989-1993 naar 59% in 2004-2008. Bij mannen was de toename in overleving groter dan bij vrouwen, respectievelijk van 40 naar 55% en van 55 naar 62%. Het meest opvallend was de verbetering in overleving bij borst-, prostaat- en darmkanker, waarschijnlijk door oorzaken die voor elk van deze kankersoorten verschillend zijn. Patiënten met chronische myeloïde leukemie lieten een grote overlevingswinst zien (toename: 43%). De overlevingskansen van oudere patiënten waren in het algemeen lager dan die van jongere, vooral bij kanker in het hoofd-halsgebied, eierstokkanker en hematologische maligniteiten. Deze kloof tussen oudere en jongere patiënten is de afgelopen 20 jaar groter geworden. De 10-jaarsoverleving was bij veel kankersoorten niet veel lager dan de 5-jaarsoverleving, behalve bij chronische en indolente hematologische maligniteiten en kanker waarbij terugkeer van de ziekte na langere tijd nog kan plaatsvinden, zoals bij borst- en prostaatkanker. Conclusie: De verbeterde overleving van kankerpatiënten in Nederland, door vroege opsporing en verbeterde behandelingen, kan wijzen op een toenemend aandeel genezen patiënten of op patiënten die langer met kanker leven. Veel winst kan nog behaald worden bij de oudere patiënt. Dit is extra van belang omdat de bevolking vergrijst
Risk of endometrial cancer after tamoxifen treatment of breast cancer
Since large trials have been set up to assess whether tamoxifen decreases the risk of breast cancer in healthy women, it has become important to investigate the drug's potential adverse effects, including occurrence of endometrial cancer. We undertook a case-cont
Chemotherapy for pulmonary large cell neuroendocrine carcinomas: Does the regimen matter?
Copyrigh
Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC)
Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of large cell neuroendocrine carcinoma (LCNEC) on biopsy specimens?
Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas
An increased association between neuroendocrine tumors of the gastrointestinal tract and pancreas (GEP-NET) and other second primary malignancies has been suggested. We determined whether there is indeed an increased risk for second primary malignancies in GEP-NET patients compared with an age- and sex-matched control group of patients with identical malignancies. The series comprised 243 men and 216 women, diagnosed with a GEP-NET between 2000 and 2009 in a tertiary referral center. The timeline, before-at-after diagnosis, and the type of other malignancies were studied using person-year methodology. Poisson distributions were used for testing statistical significance. All data were cross-checked with the Dutch National Cancer Registry. Out of 459 patients with GEP-NET, 67 (13.7%) had a second primary cancer diagnosis: 25 previous cancers (5.4%), 13 synchronous cancers (2.8%), and 29 metachronous can